Quote this publication Share Print

AKYNZEO (palonosetron + netupitant), combination setron

GASTROENTEROLOGY - ONCOLOGY - New medicinal product
Opinions on drugs - Posted on Oct 04 2017

Reason for request

Inclusion

No clinical benefit demonstrated in prevention of nausea and vomiting after highly emetogenic chemotherapy compared with the standard treatment (setron + aprepitant + corticosteroid)

Insufficient clinical benefit after moderately emetogenic chemotherapy, in the absence of clinical data

  

  • AKYNZEO has marketing authorisation in the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based chemotherapy and moderately emetogenic chemotherapy.
  • In the context of a highly emetogenic chemotherapy or anthracycline/cyclophosphamide, the available data do not make it possible to assess the benefit of AKYNZEO compared with the standard treatment (setron + corticosteroid + aprepitant) in the prevention of nausea and vomiting. The transferability and the impact on morbidity and mortality and on quality of life have not been demonstrated to date.
  • Its clinical benefit after a moderately emetogenic chemotherapy has not been established.

 

 


Clinical Benefit

Substantial

-

Insufficient

Clinical Added Value

no clinical added value

-


Therapeutic use

-

Contact Us

Évaluation des médicaments